Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

BACKGROUND: Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertamini, Luca, Nanni, Jacopo, Marconi, Giovanni, Abbenante, Mariachiara, Robustelli, Valentina, Bacci, Francesco, Matti, Antonella, Paolini, Stefania, Sartor, Chiara, Monaco, Silvia Lo, Fontana, Maria Chiara, De Polo, Stefano, Cavo, Michele, Curti, Antonio, Martinelli, Giovanni, Papayannidis, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238377/
https://www.ncbi.nlm.nih.gov/pubmed/30442119
http://dx.doi.org/10.1186/s12885-018-5026-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238377/
https://www.ncbi.nlm.nih.gov/pubmed/30442119
http://dx.doi.org/10.1186/s12885-018-5026-x

Ejemplares similares